[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638115":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":33,"responsibleParty":58,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":31,"eligibilityCriteria":70,"healthyVolunteers":67,"sex":71,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":31,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":84,"overallStatus":86,"whyStopped":31,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},{"fullName":5,"class":6},"Emory University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Suzetrigine Regimen Arm","EXPERIMENTAL","Suzetrigine (JOURNAVX®) administered orally consisting of a course that lasts up to a maximum of 14 days.\n\nThe starting dose will be 100 mg orally taken as two 50 mg tablets on an empty stomach (at least 1 hour before or 2 hours after food). Maintenance dosing will begin 12 hours after the initial dose, at which point patients will take 50 mg orally every 12 hours.",[13],"Drug: Suzetrigine",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Suzetrigine","Suzetrigine is an orally administered, selective NaV1.8 voltage-gated sodium channel inhibitor being investigated as a non-opioid analgesic for the treatment of pain through inhibition of pain signal transmission in peripheral sensory neurons.",[9],[21],"JOURNAVX®",[23],{"name":24,"affiliation":5,"role":25},"Ajay Premkumar, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":31,"email":32},"Darrell Favors","CONTACT","404-313-3276",null,"darrell.favors@emory.edu",[34,47,53],{"facility":35,"status":31,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":31},"Emory Clinic","Atlanta","Georgia","30322","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-84.38798,33.749,{"lat":45,"lon":44},{"facility":48,"status":31,"city":36,"state":37,"zip":49,"country":39,"countryCode":40,"cosmosGeoPoint":50,"geoPoint":52,"contacts":31},"Emory Clinic at Executive Park","30329",{"type":42,"coordinates":51},[44,45],{"lat":45,"lon":44},{"facility":54,"status":31,"city":36,"state":37,"zip":49,"country":39,"countryCode":40,"cosmosGeoPoint":55,"geoPoint":57,"contacts":31},"Emory Orthopaedics and Spine Center",{"type":42,"coordinates":56},[44,45],{"lat":45,"lon":44},{"type":25,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":31,"oldOrganization":31},"Ajay Premkumar","Assistant Professor",[62],{"name":63,"class":64},"Vertex Pharmaceuticals Incorporated","INDUSTRY","100638115","phase-4-role-of-suzetrigine-as-a-part-of-a-multimodal-regimen-to-reduce-pain-and-opioid-use-after-total-knee-arthroplasty-100638115",false,"NCT07624526","Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty","Inclusion Criteria:\n\n* Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee.\n* Patients between the ages of 18 and 95 years.\n\nExclusion Criteria:\n\n* Patients with concurrent and significant injuries to other bones or organs.\n* Patients with local infections.\n* Minors unable to provide informed consent for participation in the study.\n* Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures.\n* Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk.\n* Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery.\n* Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction\n* Patients with active peptic ulcer disease.\n* Patients neurological or psychiatric diseases, potentially influencing pain perception\n* Patients who are pregnant.\n* Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids.\n* Patients who are unable to take NSAIDs.\n* Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID).\n* Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%.\n* Patients currently taking CYP3A inhibitors","ALL","18 Years","95 Years",{"count":75,"type":76},75,"ESTIMATED","INTERVENTIONAL",[79],"PHASE4","This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.",[82,83],"Knee Arthritis","Knee Osteoarthritis",[85,17],"Total knee arthroplasty","NOT_YET_RECRUITING","2026-05-28",{"date":89,"type":90},"2026-06-03","ACTUAL",{"date":92,"type":76},"2026-07",{"date":94,"type":76},"2028-08",{"name":5,"class":6},3]